MACH7 TECHNOLOGIES LIMITED — Board/Management Information 2019

Jun 19, 2019

ASX Announcement

20 June 2019

==> picture [612 x 88] intentionally omitted <==

Mach7 Announces Board Changes

Melbourne, Australia; 20 June 2019: Mach7 Technologies Limited (“Mach7” or the “Company”) (ASX:M7T) today announced that Mr. Damien Lim will transition from the role of Chair of the Board to non-executive Director. Mr. David Chambers, presently a non-executive director of Mach7, will be appointed to the role of Chair. In addition, Mr. Mike Lampron, who was appointed as interim CEO on 11 March 2019, will be appointed to the Board as Managing Director. These changes are effective from Monday, 24 June 2019.

The change in the role of Chair is the first step of a planned board renewal process. The Board continues to assess its composition to ensure it has the appropriate mix of skills, experience and diversity best suited to Mach7. As part of the Board’s most recent assessment, it has determined that it will conduct a search for a new director who has deep healthcare/I.T. experience to join the Mach7 Board. The timing for this appointment is planned for later this year.

The Board is also pleased to welcome Mr. Lampron to the Board and officially appoint him as Managing Director of Mach7.

Mr. Chambers commented “Firstly, I am delighted that Mike has accepted our invitation to join the Board, and believe he adds a lot of value to Mach7, both as a director and an executive. Secondly, on behalf of my fellow directors, I would like to sincerely thank Damien for his time and efforts in performing the role of Chair over the last three years. I am excited to be taking on that role, and look forward to continuing to work with him, and my fellow directors, going forward.”

Mr. Chambers brings extensive global healthcare/I.T. industry experience to the Board. He was previously CEO of ASX-listed company Promedicus and has held senior management positions with Nasdaq-listed companies. Mr. Chambers joined the Mach7 Board on 3 August 2018.

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative data management solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7’s awardwinning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7’s sophisticated workflow tools, advanced clinical viewing and optimized vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit Mach7t.com.

==> picture [610 x 89] intentionally omitted <==

ASX Announcement

20 June 2019

==> picture [612 x 88] intentionally omitted <==

For more information, contact :

Jenni Pilcher CFO, Mach7 jenni.pilcher@mach7t.com

==> picture [610 x 89] intentionally omitted <==